Retrospective analysis of metastatic colorectal cancer based on clinical cancer registry data. Tumor biology, treatment, and outcome.

Irina Surovtsova, Daria B. Kokh, Claudia Winzler and Philipp Morakis

Krebsregister Baden-Württemberg, Geschäftsstelle Qualitätskonferenzen bei der Klinischen Landesregisterstelle GmbH, Stuttgart

Background and Objectives

- Metastatic colorectal cancer (mCRC) is one of the most common causes of cancer-related death with median overall survival (OS) between 26-36 months [1]. Important prognostic factors are the localization and tumor biology [2]. Systemic chemotherapy has been the main treatment approach for non resectable mCRC [3].
- The aim of the present study is to explore clinical and biological profile of mCRC as well as \bullet the disease treatment and patient outcome based on the data collected in the cancer registry of Baden-Württemberg state, Germany.

Methods

- Records for patients with mCRC diagnosed in 2016-2022 were selected.
- Overall survival were assessed using Kaplan-Meier statistics and multivariable Cox \bullet proportional hazard models.

BRAF and RAS Mutations vs Localisation





The following parameters were considered: age, gender, tumor localization, BRAF and \bullet RAS mutations, MSI status and systemic treatment.

Patient demographics and clinical information

- Patients in the cohort are \bullet predominantly males and elderlies
- Tumors are mostly well- or \bullet intermediately differentiated
- BRAF- and RAS mutations are found more frequently in right sided cancer
- Most carcinomas are classified as \bullet MSS/MMRp.
- MSI-H/MMRd is reported in 4.4% of cases and more often found in right sided cancer

	All patients	Right	left	Rectum	
Number (%)	1138(100)	389(34)	388(34)	361(32)	
Age median (SD)	66(12,1)	60(12)	65(11.8)	65(12.5)	
Age, median (5D)	00(12,1)	09(12)	03(11,8)	03(12,3)	
Patient sex	600(61)	200(52)	246(62)	240(C7)	
- Male (%)	699(61)	206(53)	246(63)	340(67)	
BRAF					
- wt (%)	973(86)	283(63)	349(90)	341(94)	
- mt (%)	165(14)	106(27)	39(10)	20(6)	
RAS					
- wt(%)	632(57)	181(50)	240(63)	211(59)	
- mt(%)	470(43)	181(50)	142(37)	147(41)	
- Missing	36	27	6	3	
MSI					
- MSI-H(%)	19(4,4)	14(10)	4(3)	1(1)	
- MSI-L(%)	8(1,9)	4(3)	1(1)	3(2)	
- MSS(%)	400(94)	117(87)	112(96)	171(98)	
- Missing	711	254	271	186	
Tumor grade					
- 1 or 2 (%)	754(72)	215(61)	280(78)	259(72)	
- 3 or 4 (%)	289(28)	137(39)	79(22)	73(22)	
- Missing	95	37	29	29	

Mutation and Microsatellite Status vs age

• Both BRAF- and RAS-mutations are mostly associated with right-sided-cancer



27%

27%

BRAFmt RASmt BRAFwtRASwt

• our data show that the frequency of BRAF- and RAS-Mutations increases with age (statistical significance, p=0.018)



• BRAF mutation is the most

Overall survival

Hazard ratio

MSI-H

MSI-L MSS

97%

92%

≤60 y

> 60 y



Left: BRAFmt 50 (100 43 (86) 34 (68) 27 (54) 13 (26) 21 (42) 17 (34) 54 (61) 38 (43) 72 (81) 49 (55) 31 (35) 25 (28) 187 (85) 173 (79) 148 (68) 121 (55) 96 (44) Left: RASmt 219 (100) 204 (93) 63 (43) Right: RASmt | 147 (100) 139 (95 126 (86 111 (76 45 (31) 317 (94) 188 (55) BRAFwt, RASwt 339 (100) 300 (88) 288 (85) 253 (75) 218 (64) 47 (53) 50 (56) 82 (92) 64 (72) 59 (66) 41 (46)

Therapy landscape

	CH only	CH + anti-EGFR	CH + anti-VEGF	-
Right-sided	100	14	104	
- BRAF mt	35	1	20	
- RAS mt	42	0	56	•
- BRAF, RAS wt	23	13	28	
Left-sided	104	79	75	
- BRAF mt	10	3	9	
- RAS mt	40	3	51	
- BRAF, RAS wt	54	73	15	•
Rectum	107	59	65	
- BRAF mt	8	1	4	
- RAS mt	40	0	50	
- BRAF, RAS wt	59	58	11	

- All patients received chemotherapy (mostly doublet).
- Right-sided carcinomas were treated with chemotherapy (CH) +/- anti-VEGF. EGFR directed therapy is rarely reported.
- Left-sided carcinomas wt/wt were treated with CH only, CH plus anti-EGFR or with CH plus anti-VEGF

significant prognostic factor with HR 1.8 (95% CI 1.39-2.4).

BRAF wildtype: the OS of patients with right-sided carcinomas is significantly worse compared to those with left-sided carcinomas.



Discussion and Conclusion

- In the present study tumor biology, therapy modalities, and treatment outcomes were analyzed for mCRC cases.
- Real world data from the clinical cancer registry of Baden-Württemberg were employed.
- BRAF status was confirmed as the most important prognostic factor.
- BRAF and RAS mutations as well as MSI status were associated with right-sided colon cancer.
- Right-sided tumors were also associated with greater risk of death compared to left-sided ones and to rectal cancer.
- For left-sided tumors, BRAF, RAS wt tumors anti-EGFR treatment in addition to

Right-Sided CC

Left-Sided CC + Rectum

Hazard ratio		Hazard ratio						
ade	< 61 reference			age	< 61			
uge	(N=52) 1.02			uge	(N=1/5) 101010100	T		
	(N=120) (0.66 - 1.6)		0.945		> 00 1.09 (N=217) (1.27 - 2.2)	⊢∎	<l< td=""><td>0.001</td></l<>	0.001
BRAF	wt <i>(N=134)</i> reference			BRAF	wt <i>(N=363)</i> reference	•		
	mt 1.37 (<i>N=38) (0.81 - 2.3)</i> └──	B	0.242		mt 3.18 <i>(N=29) (1.96 - 5.2)</i>	F		0.001
RAS	wt <i>(N=92)</i> reference			RAS	wt <i>(N=252)</i> reference	•		
	mt 0.99 (<i>N=80) (0.62 - 1.6)</i>	- B	0.955		mt 1.49 <i>(N=140) (1.05 - 2.1)</i>	▶₩	• 0.0	024 *
Therapy	CH only reference (N=78)			Therapy	CH only (N=178) reference			
	Anti-EGFR 1.16 (<i>N=12) (0.53 - 2.5)</i>		→ 0.711		Anti-EGFR 1.05 (<i>N=112) (0.73 - 1.5)</i>	4	0.7	785
	Anti-VEGF 1.13 (<i>N=82) (0.76 - 1.7</i>)		0.553		Anti-VEGF 0.93 <i>(N=102) (0.65 - 1.3)</i>	 1	0.6	5 7 8
# Events: 109	; Global p-value (Log-Rank): 0.83635	1 1.5 2 2	2.5	# Events: 210;	Global p-value (Log-Rank): 2.	7453e-06	5	
AIC: 985.89; Concordance Index: 0.54		AIC: 2211.12; Concordance Index: 0.62						

chemotherapy was reported for about half of the patients. No significant difference in OS was observed for patients who underwent different therapies.

- For right-sided tumors, no significant difference in OS was observed for the patients treated with CH only vs. those treated with CH plus anti-VEGF.
- Data of clinical cancer registries can be used to build an external control arm for clinical trials.

References

[1] Oliveira et al. Frontiers in Oncology (2019), 9, 396 [2] Ruiz-Bañobre J. et al, JCO Precision Oncology (2019), 3, 1-17 [3] Atreya et al., American Society of Clinical Oncology Educational Book 37 (2018) 246-256.

Contact information

Philipp Morakis

Geschäftsstelle Qualitätskonferenzen

Klinische Landesregisterstelle Baden-Württemberg GmbH

des Krebsregisters Baden-Württemberg

Birkenwaldstr. 149 70191 Stuttgart, Germany

Email: morakis@qualiko-bw.de Phone: +49 711 137909 101